Qube Research & Technologies (QRT)’s Axsome Therapeutics AXSM Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$56.7M	Buy	335,334 +9,894	+3%	+$1.71M	0.06%	385
2025 Q4	$59.4M	Sell	325,440 -186	-0.1%	-$26K	0.06%	418
2025 Q3	$39.5M	Sell	325,626 -65,991	-17%	-$7.43M	0.04%	575
2025 Q2	$40.9M	Buy	391,617 +109,241	+39%	+$11.6M	0.04%	549
2025 Q1	$32.9M	Buy	282,376 +126,465	+81%	+$14.4M	0.04%	545
2024 Q4	$13.2M	Buy	155,911 +125,541	+413%	+$11.5M	0.02%	934
2024 Q3	$2.73M	Buy	+30,370	New	+$2.65M	﹤0.01%	1641
2024 Q2	–	Sell	-1,696	Closed	-$135K	–	3808
2024 Q1	$135K	Buy	+1,696	New	+$142K	﹤0.01%	3193
2023 Q1	–	Sell	-23,786	Closed	-$1.83M	–	2537
2022 Q4	$1.83M	Sell	23,786 -98,024	-80%	-$5.86M	0.01%	973
2022 Q3	$5.43M	Buy	+121,810	New	+$6.09M	0.03%	594

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Qube Research & Technologies (QRT)'s AXSM Position: Q1 2026 in Review

Qube Research & Technologies (QRT) increased its Axsome Therapeutics (AXSM) stake by 3% in Q1 2026, buying an estimated $1.71M and bringing the position to 335,334 shares worth $56.7M. The position accounts for 0.06% of the portfolio, ranked #385.

Qube Research & Technologies (QRT) first reported a position in AXSM in Q3 2022 and has held it in 10 quarters since. The position peaked at $59.4M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Qube Research & Technologies (QRT) held 335,334 shares of Axsome Therapeutics worth $56.7M as of Q1 2026.
Qube Research & Technologies (QRT) bought 9,894 Axsome Therapeutics shares in Q1 2026, an estimated $1.71M.
Axsome Therapeutics made up 0.06% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #385 holding.
Qube Research & Technologies (QRT) first reported a position in Axsome Therapeutics in Q3 2022 and has held it in 10 quarters since.
Qube Research & Technologies (QRT)'s Axsome Therapeutics position peaked at $59.4M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.